Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeisVac-C Interference with Hep B, IPV, and aP Vaccines in Infants
NCT00161928Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2002
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal meningitis (2 arms), sponsored by Pfizer. Primary endpoints: Seroconversion rate induced by Hepatitis B vaccine, Seroconversion rate induced by Inactivated Polio Vaccine and 1 more. Started Apr 2002; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT00161928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161928.